By using CRISPR/Cas9 to engineer cells from healthy donors, AVC-203 is designed to circumvent graft-versus-host disease and host-mediated rejection.

Paediatric orbital tumours are rare, and primary orbital lymphomas are particularly uncommon, with an incidence of approximately 0.12 per 1000 000 children. Such lymphomas may present as orbital ...

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma in adults. According to the gene expression profile, it can be classified into germinal center B-cell (GCB) type ...

The FDA has updated the safety labeling for axicabtagene ciloleucel (Yescarta, Kite Oncology) ­— a CAR T-cell therapy — extending its indication to include patients with relapsed or refractory primary ...

Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of diffuse large B-cell lymphoma, with nodal involvement being particularly uncommon. Due to its atypical clinical presentation, timely ...

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma - Phase 3 frontMIND trial evaluating the ...

Several factors contribute to the development of DLBCL, including genetic predispositions, infections, and environmental exposures. The disease usually presents with generalized lymphadenopathy, and ...

(RTTNews) - Incyte Corp. (INCY) announced on Thursday that the European Commission has approved Minjuvi in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed ...

MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...

Two-year follow up from Arm 8 of the EPCORE NHL-2 trial (abstract 64) showed fixed-duration epcoritamab plus rituximab plus dose-attenuated cyclophosphamide, doxorubicin, vincristine, and prednisone ...

The FDA has approved lisocabtagene maraleucel (Breyanzi, Bristol-Myers Squibb) for relapsed or refractory marginal zone lymphoma (MZL) in adults after at least two prior lines of systemic therapy.

NEW YORK – Estrella Immunopharma said Thursday that it plans to advance the autologous CD19-targeted T-cell therapy EB103 into the Phase II portion of an ongoing clinical trial in patients with ...